Repligen (NASDAQ:RGEN) Updates FY 2024 Earnings Guidance

Repligen (NASDAQ:RGEN) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 1.420-1.490 for the period, compared to the consensus estimate of 1.460. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $635.6 million. Repligen also updated its FY24 guidance to $1.42-1.49 EPS.

Repligen Trading Up 0.4 %

NASDAQ RGEN traded up $0.74 during trading on Friday, reaching $167.05. 454,984 shares of the stock traded hands, compared to its average volume of 538,521. The firm has a market cap of $9.33 billion, a price-to-earnings ratio of 668.23, a price-to-earnings-growth ratio of 5.44 and a beta of 1.03. The stock’s 50-day moving average price is $180.81 and its 200 day moving average price is $174.09. The company has a quick ratio of 5.75, a current ratio of 6.35 and a debt-to-equity ratio of 0.26. Repligen has a fifty-two week low of $110.45 and a fifty-two week high of $211.13.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The company had revenue of $151.31 million during the quarter, compared to the consensus estimate of $150.06 million. During the same period in the previous year, the firm posted $0.64 EPS. The business’s quarterly revenue was down 17.1% compared to the same quarter last year. Analysts predict that Repligen will post 1.46 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on RGEN shares. JPMorgan Chase & Co. cut their price objective on shares of Repligen from $230.00 to $200.00 and set an overweight rating on the stock in a research report on Thursday. KeyCorp raised their price target on shares of Repligen from $210.00 to $220.00 and gave the stock an overweight rating in a research report on Thursday, February 15th. Finally, Stifel Nicolaus raised their target price on shares of Repligen from $165.00 to $207.00 and gave the company a buy rating in a report on Thursday, February 22nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Repligen has a consensus rating of Moderate Buy and a consensus price target of $197.75.

Insider Transactions at Repligen

In other news, COO James Bylund sold 4,373 shares of the business’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total value of $866,203.84. Following the transaction, the chief operating officer now owns 14,135 shares in the company, valued at approximately $2,799,860.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, COO James Bylund sold 4,373 shares of Repligen stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total value of $866,203.84. Following the completion of the sale, the chief operating officer now owns 14,135 shares in the company, valued at approximately $2,799,860.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction on Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the sale, the vice president now owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 25,597 shares of company stock worth $5,039,532. Company insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.